GLEAMER investment from Supernova Invest & Heal Capital

The leading European manufacturer in AI-powered solutions for medical imaging raises €27 million in Series B funding round to expand its AI solutions portfolio

Gleamer, the leading European manufacturer in AI-powered solutions for medical imaging, announced a Series B financing of €27 million. This operation is led by Supernova Invest, co-led by Heal Capital and backed by Gleamer’s long-term partners XAnge, Elaia, Bpi France via the funds F3A and Digital Venture, MACSF, Crista Galli Ventures, and UI Investissement, as well as several European radiologists. This new investment will enable Gleamer to expand its portfolio of solutions, strengthen its European and American teams, and accelerate its international development plans. 

Since its inception, Gleamer has developed a comprehensive suite of AI-powered solutions for standard radiography certified as Class IIa medical devices under EU MDR and partly FDA cleared. The clinical diagnostic solutions developed by Gleamer are now recognized worldwide by the scientific community, thanks to nine publications in major medical journals. Now serving over 6,500 users in 650 institutions, spanning 24 countries, its solutions process more than a million medical examinations each month. This new funding gives Gleamer the resources to achieve its strategic roadmap, and to deploy disruptive technological solutions at scale to meet the expectations of medical staff worldwide.

Tomorrow, by extending its portfolio of solutions to CT scans and mammography, Gleamer will cover 70% of radiologists' daily (or "routine") needs. The company aims to accelerate its international expansion, particularly in Europe and in the United States where the sales teams will be strengthened.

In addition, Gleamer will extend existing strategic partnerships, while signing new large-scale partnerships with local and global players in the medical imaging field, to make Gleamer's solutions accessible to as many people as possible.